{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:25Z","timestamp":1777984345525,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ninghai County Science and Technology Plan Project","award":["No. 202325"],"award-info":[{"award-number":["No. 202325"]}]},{"name":"Ninghai County Science and Technology Plan Project","award":["No. 202325"],"award-info":[{"award-number":["No. 202325"]}]},{"name":"Ninghai County Science and Technology Plan Project","award":["No. 202325"],"award-info":[{"award-number":["No. 202325"]}]},{"name":"Ninghai County Science and Technology Plan Project","award":["No. 202325"],"award-info":[{"award-number":["No. 202325"]}]},{"name":"Ninghai County Science and Technology Plan Project","award":["No. 202325"],"award-info":[{"award-number":["No. 202325"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-026-02314-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:26:54Z","timestamp":1770298014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful experience with high-risk and family screening for Fabry disease in Ninghai County, Zhejiang Province, Eastern China: genotype\u2012phenotype analysis of the GLA IVS4\u2009+\u2009919G\u2009&gt;\u2009A variant"],"prefix":"10.1186","volume":"19","author":[{"given":"Zhuhui","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangqiao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaojuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenggang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2314_CR1","unstructured":"Mehta A, Hughes DA. Fabry disease [M\/OL]. 2nd ed. Seattle (WA): University of Washington, Seattle. 2002:1\u201336. 09 Mar 2023. https:\/\/www.ncbi.nlm.NIH.Gov\/books\/NBK1292."},{"issue":"4","key":"2314_CR2","first-page":"321","volume":"60","author":"Chinese Fabry disease expert panel","year":"2021","unstructured":"Chinese Fabry disease expert panel. Expert consensus for diagnosis and treatment of Fabry disease in China (2021) . Chin J Intern Med. 2021;60(4):321\u2013330.","journal-title":"Chin J Intern Med"},{"issue":"3","key":"2314_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2314_CR4","doi-asserted-by":"publisher","first-page":"e1666","DOI":"10.1002\/mgg3.1666","volume":"9","author":"DP Germain","year":"2021","unstructured":"Germain DP, Moiseev S, Suarez-Obando F, et al. The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease. Mol Genet Genomic Med. 2021;9(5):e1666.","journal-title":"Mol Genet Genomic Med"},{"issue":"4","key":"2314_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/339431","volume":"70","author":"S Ishii","year":"2002","unstructured":"Ishii S, Nakao S, Minamikawa-Tachino R, et al. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet. 2002;70(4):994\u20131002.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2314_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA, et al. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47(4):217-22.","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"2314_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"10","key":"2314_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Kubo T, Ochi Y, Baba Y, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol. 2017;69(1):302-7.","journal-title":"Hum Mutat"},{"key":"2314_CR9","doi-asserted-by":"crossref","unstructured":"Sadasivan C, Chow J, Sheng B, et al. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. PLoS One. 2020;15(9):e239675","DOI":"10.1371\/journal.pone.0239675"},{"issue":"5","key":"2314_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1159\/000494678","volume":"43","author":"CJ Lin","year":"2018","unstructured":"Fan Y, Chan TN, Chow J, et al. High prevalence of Late-Onset Fabry cardiomyopathy in a cohort of 499 Non-Selective patients with left ventricular hypertrophy: the Asian Fabry cardiomyopathy High-Risk screening study (ASIAN-FAME). J Clin Med. 2021;10(10):2160.","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"2314_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.transproceed.2023.03.012","volume":"55","author":"CY Shih","year":"2023","unstructured":"Leung SP, Dougherty S, Zhang XY, et al. The Asian Fabry cardiomyopathy High-Risk screening study 2 (ASIAN-FAME-2): prevalence of Fabry disease in patients with left ventricular hypertrophy. J Clin Med. 2024;13(13):3896.","journal-title":"Transpl Proc"},{"issue":"8","key":"2314_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Lee TH, Yang JT, Lee JD, et al. Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature. Eur J Neurol. 2019;26(3):553-5.","journal-title":"J Hum Genet"},{"issue":"1","key":"2314_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s10038-017-0366-y","volume":"63","author":"YH Lu","year":"2018","unstructured":"Lin CJ, Chien YH, Lai TS, et al. The results of Fabry Disease screening in male Pre-End stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a Northern Taiwan medical center. Kidney Blood Press Res. 2018;43(5):1636-45.","journal-title":"J Hum Genet"},{"issue":"3","key":"2314_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ene.13775","volume":"26","author":"TH Lee","year":"2019","unstructured":"Shih CY, You ZH, Tsai SF, et al. Diagnosis and management of Fabry Disease in High-Risk renal disease patients in Taiwan: a single center study. Transpl Proc. 2023;55(4):788-91.","journal-title":"Eur J Neurol"},{"key":"2314_CR15","doi-asserted-by":"publisher","first-page":"117889","DOI":"10.1016\/j.cca.2024.117889","volume":"557","author":"Y Sun","year":"2024","unstructured":"Chen BR, Tong MQ, Lu ZH, et al, High-risk screening combined with family screening for Fabry disease in adult hemodialysis population-a family report of GLA IVS4+919 G>A mutation in Fabry disease. Clin J of Nephrol, 2024,40(1):18-23.","journal-title":"Clin Chim Acta"},{"key":"2314_CR16","doi-asserted-by":"crossref","unstructured":"Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30(10):1397-405.","DOI":"10.1002\/humu.21074"},{"issue":"4","key":"2314_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Inoue T, Hattori K, Ihara K, et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58(8):548-52.","journal-title":"J Med Genet"},{"issue":"9","key":"2314_CR18","doi-asserted-by":"publisher","first-page":"e239675","DOI":"10.1371\/journal.pone.0239675","volume":"15","author":"C Sadasivan","year":"2020","unstructured":"Sun Y, Guan XW, Wang YY, et al. Newborn genetic screening for Fabry disease: Insights from a retrospective analysis in Nanjing, China. Clin Chim Acta. 2024;557:117889.","journal-title":"PLoS ONE"},{"key":"2314_CR19","doi-asserted-by":"crossref","unstructured":"Chang S, Zhan X, Liu Y, et al. Newborn screening for 6 lysosomal storage disorders in China. JAMA Netw Open. 2024;7(5):e2410754","DOI":"10.1001\/jamanetworkopen.2024.10754"},{"issue":"4","key":"2314_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jmg.2009.072116","volume":"47","author":"GE Linthorst","year":"2010","unstructured":"Moiseev S, Tao E, Moiseev A, et al. The benefits of family screening in rare diseases: genetic testing reveals 165 new cases of Fabry disease among At-Risk family members of 83 index patients. Genes (Basel). 2022;13(9):1619.","journal-title":"J Med Genet"},{"issue":"5","key":"2314_CR21","doi-asserted-by":"publisher","first-page":"e2410754","DOI":"10.1001\/jamanetworkopen.2024.10754","volume":"7","author":"S Chang","year":"2024","unstructured":"Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450-6.","journal-title":"JAMA Netw Open"},{"key":"2314_CR22","doi-asserted-by":"crossref","unstructured":"Liang KH, Lu YH, Niu CW, et al. The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago. J Hum Genet. 2020;65(7):619-25.","DOI":"10.1038\/s10038-020-0745-7"},{"issue":"1","key":"2314_CR23","first-page":"18","volume":"40","author":"BR Chen","year":"2024","unstructured":"Hsu TR, Chang FP, Chu TH, et al. Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey. Int J Mol Sci. 2017;18(1):119.","journal-title":"Clin J Nephrol"},{"issue":"23","key":"2314_CR24","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","volume":"68","author":"TR Hsu","year":"2016","unstructured":"Hsu TR, Hung SC, Chang FP, et al. Later onset Fabry Disease, cardiac damage progress in silence: experience with a highly prevalent Mutation. J Am Coll Cardiol. 2016;68(23):2554\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"2314_CR25","doi-asserted-by":"crossref","unstructured":"Hsu TR, Niu DM. Fabry disease: Review and experience during newborn screening. Trends Cardiovasc Med. 2018;28(4):274-81.","DOI":"10.1016\/j.tcm.2017.10.001"},{"issue":"4","key":"2314_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Lin HY, Huang CH, Yu HC, et al. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919GA). J Inherit Metab Dis. 2010;33(5):619-24.","journal-title":"Trends Cardiovasc Med"},{"key":"2314_CR27","doi-asserted-by":"crossref","unstructured":"Lin HY, Liu HC, Huang YH et al. Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4\u2009+\u2009919G\u2009>\u2009A). BMJ Open. 2013;3(7):e3146.","DOI":"10.1136\/bmjopen-2013-003146"},{"issue":"5","key":"2314_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10545-010-9166-7","volume":"33","author":"HY Lin","year":"2010","unstructured":"Hsu TR, Sung SH, Chang FP, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis. 2014;9:96.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2314_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lee HJ, Hung SC, Hsu TR, et al. Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation. AJNR Am J Neuroradiol. 2016;37(6):1044-9.","journal-title":"Circ Cardiovasc Genet"},{"issue":"7","key":"2314_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s10038-020-0745-7","volume":"65","author":"KH Liang","year":"2020","unstructured":"Ge ZH, Lu ZH, Pan XD, et al. Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree. Chin J Pediatr. 2024;62(4):345-50.","journal-title":"J Hum Genet"},{"key":"2314_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1750-1172-9-96","volume":"9","author":"TR Hsu","year":"2014","unstructured":"Fledelius HC, Sandfeld L, Rasmussen AK, et al. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement. Acta Ophthalmol. 2015;93(3):258-64.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2314_CR32","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3174\/ajnr.A4677","volume":"37","author":"HJ Lee","year":"2016","unstructured":"Sher NA, Reiff W, Letson RD, et al. Central retinal artery occlusion complicating Fabry's disease. Arch Ophthalmol. 1978;96(5):815-7.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"2314_CR33","first-page":"345","volume":"62","author":"ZH Ge","year":"2024","unstructured":"Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol. 1979;97(4):671-6.","journal-title":"Chin J Pediatr"},{"issue":"3","key":"2314_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/aos.12588","volume":"93","author":"HC Fledelius","year":"2015","unstructured":"Favalli V, Disabella E, Molinaro M, et al. Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics. J Am Coll Cardiol, 2016,68(10):1037-1050.","journal-title":"Acta Ophthalmol"},{"key":"2314_CR35","unstructured":"Zhejiang Healthcare Security Administration, Zhejiang Provincial Department of Finance, Health Commission of Zhejiang Province, et al. Circular on the establishment of drug guarantee mechanism for rare diseases in Zhejiang Province. Gaz Zhejiang Provincial People's Gov. 2020;(02):33-35. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=ZJZE202002010&DbName=CJFN2020."},{"key":"2314_CR36","unstructured":"National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, et al. Circular of publishing the first list of rare diseases. Gaz Minist Health People's Repub China. 2018;(5):15-19. https:\/\/www.gov.cn\/zhengce\/zhengceku\/2018-12\/31\/content_5435167.htm."},{"key":"2314_CR37","unstructured":"Chen N. Fabry disease: timely diagnosis and treatment, improve clinical outcome. Zhonghua Nei Ke Za Zhi. 2021;60(4):299-301."}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-026-02314-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:01:43Z","timestamp":1773061303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-026-02314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1186\/s12920-026-02314-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6363208\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethics approval for this study was granted by the Ethics Board of Ninghai First Hospital (project number: Nhyy-IEC-KY202304). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}